GlassScriptPhysician profile
Demetria Mcduffey
NPI 1508550872
$2,477.05
in general payments reported to CMS, 2019-2025
36 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $564 · 2024: $791 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.93 | 2023-2025 | |
| Pfizer INC. | $244.15 | 2024-2025 | |
| Lilly USA, LLC | $216.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $184.52 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $178.29 | 2025 | Auvelity |
| Novo Nordisk INC | $143.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Antares Pharma, INC. | $137.94 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.64 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $93.60 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $90.09 | 2025 | Fanapt |
| Radius Health, INC. | $74.62 | 2023-2024 | Tymlos |
| Viiv Healthcare Company | $69.05 | 2025 | Cabenuva, Apretude, Rukobia |
| Amgen INC. | $60.50 | 2023-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $60.05 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $50.80 | 2024-2025 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $36.18 | 2023-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $31.49 | 2025 | Zerbaxa |
| Gilead Sciences, INC. | $28.22 | 2023-2024 | Veklury |
| Dynavax Technologies Corporation | $27.69 | 2024-2025 | Heplisav-B |
| Alkermes, INC. | $26.70 | 2023 | Vivitrol |
| Abbott Laboratories | $22.87 | 2025 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.54 | 2025 | Rexulti |
| Insulet Corporation | $20.49 | 2024 | Omnipod |
| Viatris Specialty LLC | $18.91 | 2025 | Yupelri |
| Halozyme INC | $17.59 | 2023 | |
| Abiomed | $16.97 | 2025 | |
| Tactile Systems Technology INC | $16.31 | 2024 | Flexitouch Plus, Entre Plus |
| Averitas Pharma INC. | $16.28 | 2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.18 | 2024 | Xifaxan |
| Melinta Therapeutics, LLC | $14.82 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Alexion Pharmaceuticals, INC. | $14.79 | 2023 | Ultomiris |
| Seqirus USA INC | $14.25 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| E.R. Squibb & Sons, L.L.C. | $14.19 | 2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2024 | Trintellix |
| Sanofi Pasteur INC. | $13.94 | 2023 | |
| Eisai INC. | $13.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetria Mcduffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.